HK Stock Market Move | BOAN BIOTECH (06955) rose more than 6% and the Disifinib injection was approved to be listed in Bolivia. Plans to submit application for market approval in multiple countries.

BOAN BIOTECH (06955) rose over 6%, as of the time of publication, it has increased by 6.28% to HK$9.98, with a turnover of HK$49.8845 million. On the news front, on January 11, BOAN BIOTECH announced that its self-developed Denosumab Injection (60mg) (code BA6101) has been approved for listing by the Bolivian National Pharmaceutical and Health Technology Bureau (AGEMED). BA6101 is a biosimilar of the original reference drug Prolia, which is widely used globally for the treatment of osteoporosis. BA6101 has the same indications as the original reference drug. BA6101 is developed based on the company's global R&D strategy and is planned to be commercialized in multiple countries and regions around the world. Currently, the listing application for BA6101 in the UK is in the approval stage, and the company plans to submit listing applications in Europe, the United States, Japan, and other countries and regions.